Subscribe To

Price Alert Latest News Economic Calendar News

CGEN / Compugen Ltd. (CGEN) Q3 2022 Earnings Call Transcript

Compugen Ltd. (NASDAQ:CGEN ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Yvonne Naughton - Head, Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Henry Adewoye - Chief Medical Officer Eran Ophir - Senior Vice President, Research and Drug Discovery Alberto Sessa - Chief Financial Officer Conference Call Participants Stephen Willey - Stifel Mark Breidenbach - Oppenheimer Reni Benjamin - JMP Securities Daina Graybosch - SVB Securities Tony Butler - ROTH Capital Operator Ladies and gentlemen, thank you for joining us today. Read More

Demo Live Account See Partner Details

Content Topics

Compugen

Ltd

CGEN

2022

Earnings

Call

Transcript

cgen

Stock

Posted: Nov 15 2022, 01:14

Author Name: Seeking Alpha

CGEN News

By Market Watch
October 9, 2023

These Israeli pharmaceutical stocks are down in the wake of Hamas attack

Shares of Israeli pharmaceutical companies took a hit in premarket trades Monday after Hamas' attack on Israel.

By Zacks Investment Research
August 29, 2023

Has Compugen (CGEN) Outpaced Other Medical Stocks This Year?

Here is how Compugen (CGEN) and Corcept Therapeutics (CORT) have performed compared to their sector so far this year.

By Seeking Alpha
May 15, 2023

Compugen Ltd. (CGEN) Q1 2023 Earnings Call Transcript

Compugen Ltd. (NASDAQ:CGEN ) Q1 2023 Earnings Conference Call May 15, 2023 8:30 AM ET Company Participants Yvonne Naughton - Head of Investor Relation

By The Motley Fool
February 28, 2023

Why Compugen Shares Are Up Today

The company released its fourth-quarter and full-year results after the bell Monday.

By Seeking Alpha
February 27, 2023

Compugen Ltd. (CGEN) Q4 2022 Earnings Call Transcript

Compugen Ltd. (NASDAQ:CGEN ) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Yvonne Naughton - Head, IR and Corpora

By PRNewsWire
February 13, 2023

Compugen to Release Fourth Quarter and Full Year 2022 Results on Monday, February 27, 2023

HOLON, Israel , Feb. 13, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computation

By The Motley Fool
February 8, 2023

Why Compugen Stock Got Slammed Today

Clinical-stage biotechs are particularly susceptible to shifts in analyst sentiment.

By The Motley Fool
December 29, 2022

Why Shares of Compugen Rose on Thursday

The clinical-stage biotech retreated a bit from one of its biggest days in a while.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.